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Letters to the Editor
Oestrogen receptors in primary breast cancer
Sir - We read with interest the recent article by
Alanko et al. (1984) reporting no significant
correlation between oestrogen receptor status in
primary breast cancer and disease free interval.
These findings were based on 263 consecutive
patients with a minimum follow-up of 24 months.
Our results on a series of 643 patients with a
follow-up of 4-10 years are at variance with their
findings. The series is similar in that only 26
patients have received adjuvant chemotherapy. A
previous communication from our unit reported an
overall correlation between ER status and disease-
free interval (Blamey et al., 1980). This correlation is
not maintained with longer follow-up. A strong
relationship also existed between tumour grade and
disease-free interval at that time. There remains a
strong relationship between grade and disease-free
interval and also between tumour grade and
oestrogen receptor status of the primary tumour
(Table I).
After stratification of our patients according to
Table I Relationship between tumour grade and
oestrogen receptor status.
Grade I Grade 2 Grade 3
ER negative 27 80 157
ER positive 1 157 138
x2=35.7025; 2 df; P= <0.001.
lymph node status we continue to observe a
significant relationship between DFI and ER status
in those patients lymph node positive at
mastectomy. This is not seen in node negative
patients (Figure 1). This relationship has been
maintained over 5-10 year of follow-up.
We also continue to find a significant correlation
between survival and ER status in those patients
lymph node positive at mastectomy; again this is
not seen in node negative patients (Figure 2).
1a r
0.8 h
0.6
0.4 [-
02
I I I I I I I It I
6 12 18 24 30 36 42 48 54 60
Time (months)
66 72 78 84 90
Figure 1 Disease-free interval. (0) node negative; ER-: (0) node negative, ER+ (n=335); (U) node
positive, ER+ (n= 190); (A) node positive, ER- (n=118).908 LETTERS TO THE EDITOR
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Figure 2 Survival. (0) node negative; ER-; (x) node negative, ER+ (n=335); (R) node positive, ER+
(n= 190); (A) node positive, ER- (n= 118).
We have previously reported an association
between the site of first metastases and ER status.
ER positive patients preferentially metastasise to
bone (Campbell et al., 1981). We suggest that this
early finding of a relationship between disease-free
interval and ER status, before stratification
according to node positivity, may in part be due to
the consistently short disease-free interval in those
patients presenting with visceral metastases
associated with ER negative tumours.
Yours etc.
M.R. Williams', R.I. Nicholson3, C.W. Elston2,
J. Todd', K. Griffiths3 & R.W. Blamey,
Depts. of 'Surgery and 2Pathology,
Nottingham City Hospital and
3Tenovus Institute, Cardiff, UK.
References
ALANKO, A., HEINONEN, E., SCHEININ, T.M.,
TOLPPANEN, E.-M. & VIHKO, R. (1984). Oestrogen and
progesterone receptors and disease-free interval in
primary breast cancer. Br. J. Cancer, 50, 667.
BLAMEY, R.W., BISHOP, H.M., BLAKE, J.R.S. & 5 others.
(1980). Relationship between primary breast tumour
receptor status and patient survival. Cancer, 46, 2765.
CAMPBELL, F.C., BLAMEY, R.W., ELSTON, C.W.,
NICHOLSON, R.I., GRIFFITHS, K. & HAYBITTLE, J.L.
(1981). Oestrogen receptor status and sites of
metastasis in breast cancer. Br. J. Cancer, 44, 456-459.
Dr. Alanko and colleagues reply:
Sir - We are satisfied in observing that our paper
has raised the interest of Dr Williams and others.
In our paper we also stress that adjuvant treatment
may be an important source of error if we want to
evaluate the possible association between receptor
status and disease-free interval. In addition, we also
observe in that report that the results of Blamey et
al. (1980) are not identical with ours despite the
fact that in both studies this point had been
accounted for. The main difference is that Blamey
et al. (1980) find that in patients with node
involvement oestrogen receptor positive tumours